Suppr超能文献

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-双(三氟甲基)苯基]乙酰基]-2-(3,4-二氯苯基)-2-吗啉基]乙基]-4-哌啶基)-2-甲基丙酰胺],速激肽神经激肽-1受体的中枢活性非肽拮抗剂:I.生化和药理学特性

SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.

作者信息

Emonds-Alt Xavier, Proietto Vincenzo, Steinberg Régis, Oury-Donat Florence, Vigé Xavier, Vilain Pol, Naline Emmanuel, Daoui Samira, Advenier Charles, Le Fur Gérard, Maffrand Jean-Pierre, Soubrié Philippe, Pascal Marc

机构信息

Sanofi-Synthélabo Recherche, Montpellier, France.

出版信息

J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. doi: 10.1124/jpet.102.040162.

Abstract

The biochemical and pharmacological properties of a novel antagonist of the tachykinin neurokinin 1 (NK1) receptor, SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], were evaluated. SSR240600 inhibited the binding of radioactive substance P to tachykinin NK1 receptors in human lymphoblastic IM9 cells (K(i) = 0.0061 nM), human astrocytoma U373MG cells (K(i) = 0.10 nM), and human brain cortex (IC50 = 0.017 nM). It also showed subnanomolar affinity for guinea pig NK1 receptors but was less potent on rat and gerbil NK1 receptors. SSR240600 inhibited [Sar(9),Met(O2)(11)]substance P-induced inositol monophosphate formation in human astrocytoma U373MG cells with an IC50 value of 0.66 nM (agonist concentration of 100 nM). It also antagonized substance P-induced contractions of isolated human small bronchi with a pIC50 value of 8.6 (agonist concentration of 100 nM). The compound was >100- to 1000-fold more selective for tachykinin NK1 receptors versus tachykinin NK2 or NK3 receptors as evaluated in binding and in vitro functional assays. In vivo antagonistic activity of SSR240600 was demonstrated on tachykinin NK1 receptor-mediated hypotension in dogs (3 and 10 microg/kg i.v.), microvascular leakage (1 and 3 mg/kg i.p.), and bronchoconstriction (50 and 100 microg/kg i.v.) in guinea pigs. It also prevented citric acid-induced cough in guinea pigs (1-10 mg/kg i.p.), an animal model in which central endogenous tachykinins are suspected to play a major role. In conclusion, SSR240600 is a new, potent, and centrally active antagonist of the tachykinin NK1 receptor, able to antagonize various NK1 receptor-mediated pharmacological effects in the periphery and in the central nervous system.

摘要

对速激肽神经激肽1(NK1)受体新型拮抗剂SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-双(三氟甲基)苯基]乙酰基]-2-(3,4-二氯苯基)-2-吗啉基]乙基]-4-哌啶基)-2-甲基丙酰胺]的生化和药理学特性进行了评估。SSR240600抑制放射性物质P与人淋巴细胞系IM9细胞(K(i)=0.0061 nM)、人星形细胞瘤U373MG细胞(K(i)=0.10 nM)和人脑皮质(IC50=0.017 nM)中速激肽NK1受体的结合。它对豚鼠NK1受体也表现出亚纳摩尔亲和力,但对大鼠和沙鼠NK1受体的效力较低。SSR240600抑制人星形细胞瘤U373MG细胞中[Sar(9),Met(O2)(11)]物质P诱导的肌醇单磷酸形成,IC50值为0.66 nM(激动剂浓度为100 nM)。它还拮抗物质P诱导的离体人小支气管收缩,pIC50值为8.6(激动剂浓度为100 nM)。在结合和体外功能试验中评估,该化合物对速激肽NK1受体的选择性比对速激肽NK2或NK3受体高100至1000倍。SSR240600在犬体内对速激肽NK1受体介导的低血压(静脉注射3和10 μg/kg)、豚鼠微血管渗漏(腹腔注射1和3 mg/kg)和支气管收缩(静脉注射50和100 μg/kg)具有体内拮抗活性。它还能预防柠檬酸诱导的豚鼠咳嗽(腹腔注射1-10 mg/kg),在该动物模型中,中枢内源性速激肽被怀疑起主要作用。总之,SSR240600是一种新型、强效且具有中枢活性的速激肽NK1受体拮抗剂,能够拮抗外周和中枢神经系统中各种NK1受体介导药理作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验